Real-world evidence is the latest global theme that is enabling organisations to analyse and review patterns from millions of clinical records of existing diabetic patients
On the occasion of National Doctors’ Day, Technology, Healthcare, Big Data Analytics (THB) has partnered with the Research Society for the Study of Diabetes in India (RSSDI) to drive hassle-free research in diabetes with a vision to generate cutting-edge clinical trends on one of the largest diabetes markets, and leverage clinical evidence to drive personalised care and deliver tangible data-backed clinical improvements, a statement notified.
It also mentioned that real-world evidence is the latest global theme that is enabling organisations to analyse and review patterns from millions of clinical records of existing diabetic patients. It enables understanding of disease burden across micro-markets, degree of under-diagnosis and under-treatment, lack of compliance, preference of molecules-basis patient cohorts and complaints, drivers of treatment switching, effectiveness of molecules in the real world, cost economics of treatments basis total cost and net clinical improvement, and most importantly, drivers of improvement and deterioration of clinical outcomes in the real-world settings.
Speaking in this regard, Lavina Yadav, Head, RWE Strategy and Operations, said, “We are honoured to be working with RSSDI to expand the generation and adoption of real-world evidence in diabetes. With the size of the country and the extent of diabetes prevalence, we believe that this collaboration has the power to make India as the largest producer of medical research on diabetes in the world.”
Adding to it, Dr Banshi Saboo, President, RSSDI and Dr Sanjay Agarwal, Secretary RSSDI said, “We are glad to be working with THB, and are happy that it is playing a front-runner role in real-world evidence in diabetes, along with RSSDI. Over the next few years, we aim to publish over 100 research articles, drive education across more than 100K physicians, and provide evidence-based care across more than one million diabetes patients along with THB.”